KLF15-activating Twist2 ameliorated hepatic steatosis by inhibiting inflammation and improving mitochondrial dysfunction via NF-κB-FGF21 or SREBP1c-FGF21 pathway.

MLA

Zhou, Lulu, et al. “KLF15-Activating Twist2 Ameliorated Hepatic Steatosis by Inhibiting Inflammation and Improving Mitochondrial Dysfunction via NF-ΚB-FGF21 or SREBP1c-FGF21 Pathway.” FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology, vol. 33, no. 12, Dec. 2019, pp. 14254–69. EBSCOhost, https://doi.org/10.1096/fj.201901347RR.

APA

Zhou, L., Li, Q., Chen, A., Liu, N., Chen, N., Chen, X., Zhu, L., Xia, B., Gong, Y., & Chen, X. (2019). KLF15-activating Twist2 ameliorated hepatic steatosis by inhibiting inflammation and improving mitochondrial dysfunction via NF-κB-FGF21 or SREBP1c-FGF21 pathway. FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology, 33(12), 14254–14269. https://doi.org/10.1096/fj.201901347RR

Chicago

Zhou, Lulu, Qinjin Li, Ao Chen, Na Liu, Ning Chen, Xiaojun Chen, Lin Zhu, Benzeng Xia, Yuqing Gong, and Xiaodong Chen. 2019. “KLF15-Activating Twist2 Ameliorated Hepatic Steatosis by Inhibiting Inflammation and Improving Mitochondrial Dysfunction via NF-ΚB-FGF21 or SREBP1c-FGF21 Pathway.” FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology 33 (12): 14254–69. doi:10.1096/fj.201901347RR.